ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $18 | -69.0% | 200 | -81.1% | 0.00% | -75.0% |
Q2 2023 | $58 | +262.5% | 1,060 | +92.7% | 0.01% | +300.0% |
Q1 2023 | $16 | -33.3% | 550 | -31.2% | 0.00% | 0.0% |
Q4 2022 | $24 | -100.0% | 800 | -87.9% | 0.00% | -33.3% |
Q3 2022 | $54,000 | -67.1% | 6,600 | +272.5% | 0.00% | -72.7% |
Q2 2022 | $164,000 | -85.7% | 1,772 | -96.2% | 0.01% | -82.0% |
Q1 2022 | $1,149,000 | +3606.5% | 46,955 | +3378.1% | 0.06% | +6000.0% |
Q3 2021 | $31,000 | -22.5% | 1,350 | -77.5% | 0.00% | -50.0% |
Q1 2021 | $40,000 | -68.8% | 6,000 | 0.0% | 0.00% | -66.7% |
Q4 2020 | $128,000 | +91.0% | 6,000 | +270.4% | 0.01% | +50.0% |
Q3 2020 | $67,000 | +13.6% | 1,620 | -67.6% | 0.00% | 0.0% |
Q2 2020 | $59,000 | -82.7% | 5,000 | -57.3% | 0.00% | -77.8% |
Q1 2020 | $341,000 | -3.9% | 11,700 | -20.9% | 0.02% | -18.2% |
Q4 2019 | $355,000 | +17650.0% | 14,800 | +393.3% | 0.02% | – |
Q3 2019 | $2,000 | -97.4% | 3,000 | -84.6% | 0.00% | -100.0% |
Q2 2019 | $76,000 | -84.2% | 19,500 | -61.9% | 0.01% | -86.0% |
Q1 2019 | $481,000 | +117.6% | 51,200 | +72.4% | 0.05% | +138.1% |
Q4 2018 | $221,000 | +176.2% | 29,700 | +120.0% | 0.02% | +250.0% |
Q3 2018 | $80,000 | +17.6% | 13,500 | +193.5% | 0.01% | +20.0% |
Q2 2018 | $68,000 | – | 4,600 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |